1. Private Manufacturers’ Thresholds to Invest in Comparative Effectiveness Trials

   • Anirban Basu
   • David Meltzer

   Leading Article 27 December 2012 Pages: 859 - 868

2. New Clinical Insights into Chronic Obstructive Pulmonary Disease and Their Implications for Pharmacoeconomic Analyses

   • Douglas W. Mapel
   • Melissa H. Roberts

   Practical Application Open access 27 December 2012 Pages: 869 - 885

3. Counting the Cost of Not Costing HIV Health Facilities Accurately

   • Eduard J. Beck
   • Carlos Avila
   • Paul De Lay

   Review Article 27 December 2012 Pages: 887 - 902

   

4. The Cost Effectiveness of Newer Epilepsy Treatments

   • Kristian Bolin
   • Lars Forsgren

   Systematic Review 27 December 2012 Pages: 903 - 923

   

5. The State of Health Economic Research in South Africa

   • Paul Gavaza
   • Karen L. Rascati
   • Star Khoza

   Systematic Review 27 December 2012 Pages: 925 - 940

   

6. Value-of-Information Analysis to Reduce Decision Uncertainty Associated with the Choice of Thromboprophylaxis after Total Hip Replacement in the Irish Healthcare Setting

   • Laura McCullagh
   • Cathal Walsh
   • Michael Barry

   Original Research Article 27 December 2012 Pages: 941 - 959

   

7. Patient Preferences for Community Pharmacy Asthma Services

   • Pradnya Naik-Panvelkar
   • Carol Armour
   • Bandana Saini

   Original Research Article 27 December 2012 Pages: 961 - 976

   

8. Validity of Cost and Utility Results?

   • Alex Diamantopoulos
   • Laura Sawyer
   • Nguyen CM Bounthavong

   Correspondence 27 December 2012 Pages: 977 - 977

9. The Authors’ Reply

   • Mark Bounthavong
   • Christine M. Nguyen
   • Anthony P. Morreale

   Correspondence 27 December 2012 Pages: 977 - 978

   

10. Is There a Role for Pharmacoeconomics in Decision Making?

    • Johan C. F. van Luijn

    Correspondence 27 December 2012 Pages: 979 - 979

11. The Authors’ Reply

    • Ties Hoomans
    • Johan L. Severens
    • Gepke O. Delwel

    Correspondence 27 December 2012 Pages: 980 - 980